Literature DB >> 9211197

Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria.

F Mazurier1, F Moreau-Gaudry, S Salesse, C Barbot, C Ged, J Reiffers, H de Verneuil.   

Abstract

Congenital erythropoietic porphyria (CEP) is an inherited metabolic disorder characterized by an overproduction and accumulation of porphyrins in bone marrow. This autosomal recessive disease results from a deficiency of uroporphyrinogen III synthase (UROIIIS), the fourth enzyme of the haem biosynthetic pathway. It is phenotypically heterogeneous: patients with mild disease have cutaneous involvement, while more severely affected patients are transfusion dependent. The cloning of UROIIIS cDNA and genomic DNA has allowed the molecular characterization of the genetic defect in a number of families. To date, 22 different mutations have been characterized. Allogeneic bone marrow transplantation is the only curative treatment available for the severe, transfusion-dependent, cases. When bone marrow transplantation cannot be performed owing to the absence of a suitable donor, the autografting of genetically modified cells is an appealing alternative. The best approach to somatic gene therapy in this disease involves the use of recombinant retroviral vectors to transduce cells ex vivo, followed by autologous transplantation of the genetically modified cells. We investigated retroviral transfer in deficient human fibroblasts, immortalized lymphoblasts as well as bone marrow cells, and obtained a complete restoration of the enzymatic activity and full metabolic correction. Using K562 cells, an erythroleukaemic cell line, the expression of the transgene remained stable during 3 months and during erythroid differentiation of the cells. Finally, a 1.6- to 1.9-fold increase in enzyme activity compared to the endogenous level was found in normal CD34+ cells, a population of heterogeneous cells known to contain the progenitor/stem cells for long-term expression. The future availability of a mouse model of the disease will permit ex vivo gene therapy experiments on the entire animal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9211197     DOI: 10.1023/a:1005365008147

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  32 in total

1.  Engraftment of immune-deficient mice with human hematopoietic stem cells.

Authors:  S Kamel-Reid; J E Dick
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

2.  A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.

Authors:  A Fontanellas; M Bensidhoum; R Enriquez de Salamanca; A Moruno Tirado; H de Verneuil; C Ged
Journal:  Eur J Hum Genet       Date:  1996       Impact factor: 4.246

3.  Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy.

Authors:  A Larochelle; J Vormoor; H Hanenberg; J C Wang; M Bhatia; T Lapidot; T Moritz; B Murdoch; X L Xiao; I Kato; D A Williams; J E Dick
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

Review 4.  Porphyrias: animal models and prospects for cellular and gene therapy.

Authors:  H de Verneuil; C Ged; S Boulechfar; F Moreau-Gaudry
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

5.  Biochemical diagnosis of a fatal case of Günther's disease in a newborn with hydrops foetalis.

Authors:  L Verstraeten; N Van Regemorter; A Pardou; H de Verneuil; V Da Silva; F Rodesch; D Vermeylen; C Donner; J C Noël; Y Nordmann
Journal:  Eur J Clin Chem Clin Biochem       Date:  1993-03

6.  [Congenital erythropoietic porphyria. Apropos of a fatal case in the neonatal period due to acute hemolysis with hepatic failure].

Authors:  H de Verneuil; F Moreau-Gaudry; C Ged; M Bensidhoum; I Hombrados; J Tricoire; M Rolland
Journal:  Arch Pediatr       Date:  1995-08       Impact factor: 1.180

7.  Identification of two new mutations in congenital erythropoietic porphyria.

Authors:  M Bensidhoum; C Ged; I Hombrados; F Moreau-Gaudry; R S Hift; P Meissner; E D Sturrock; H de Verneuil
Journal:  Eur J Hum Genet       Date:  1995       Impact factor: 4.246

8.  Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice.

Authors:  T Lapidot; F Pflumio; M Doedens; B Murdoch; D E Williams; J E Dick
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

9.  Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene.

Authors:  C A Warner; H W Yoo; A G Roberts; R J Desnick
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

10.  Metabolic correction of congenital erythropoietic porphyria by retrovirus-mediated gene transfer into Epstein-Barr virus-transformed B-cell lines.

Authors:  F Moreau-Gaudry; F Mazurier; M Bensidhoum; C Ged; H de Verneuil
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

View more
  2 in total

Review 1.  [Hepatic porphyrias and alcohol].

Authors:  M O Doss; A Kühnel; U Gross; I Sieg
Journal:  Med Klin (Munich)       Date:  1999-06-15

Review 2.  Erythropoietic and hepatic porphyrias.

Authors:  U Gross; G F Hoffmann; M O Doss
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.